Probiotics for Immune System Enhancement

Obtaining and amplifying a patient's lung microbiome for personalized medicine applications like prognosis, antibiotic testing, and transplantation. The method involves culturing bronchoalveolar lavage samples in specific media to expand the lung bacteria populations.

Source

An antiviral probiotic that can effectively prevent and treat viral infections. The probiotic contains strains of Lactobacillus bacteria that have been selected for their ability to enhance expression of antiviral factors and reduce expression of factors that inhibit antiviral activity. The strains also have 16S rRNA gene sequences similar to the selected strains. Administering these probiotic strains can boost the body's natural antiviral defenses and provide protection against viral infections, including combined viral and bacterial infections.

Source

Compositions and formulations containing live microbial populations isolated from plants that can be used to treat and/or prevent immune system disorders, and conditions related to inflammation. The compositions can be in the form of pharmaceutical compositions, medical foods, dietary supplements, or solid food stuffs. The formulations can contain specific plant-derived bacterial and fungal species that can reduce inflammation when ingested.

Source

Compound probiotic that improves immunity by combining three specific strains: Bifidobacterium animalis subsp. lactis BLa80, Lactobacillus rhamnosus LRa05, and Lactobacillus acidophilus LA05. Administering this combination of probiotics together synergistically enhances immune function compared to using any one strain alone. It increases antioxidant levels, reduces inflammation, boosts immunoglobulin production, and increases intestinal defensin expression.

Source

Compositions containing specific probiotic strains for preventing and treating gastrointestinal disorders like inflammatory bowel disease. The compositions comprise a probiotic blend including strains from Lactobacillus (plantarum, acidophilus, helveticus, gasseri) and Bifidobacterium (lactis, breve, longum, infantis) genera. The strains can be used alone or in combination. The compositions can be foods or pharmaceuticals and are intended for preventing and treating gastrointestinal disorders like IBD.

Source

Anti-allergic probiotic agent for preventing, alleviating or treating allergic reactions. The probiotic agent is a combination of two strains: Bifidobacterium animalis subsp. lactis BLa36 and Lactobacillus casei LC89. The specific strains and ratios were identified through experiments to synergistically reduce allergic symptoms like IgE levels, histamine release, and allergy gene expression.

Source

Composition containing specific strains of lactic acid bacteria, such as Lactobacillus paracasei MCC1849, to activate plasmacytoid dendritic cells (pDCs). The composition can be used to maintain, improve, or strengthen immune function by activating pDCs, which are important immune cells involved in virus defense and immune cell activation. The lactic acid bacteria strains increase expression of the activation marker CD86 on pDCs.

Source

Rimosyllactobacillus fermentum strain MG4538 with immune system enhancing properties suitable for use as an immune system boosting probiotic. The strain, deposited as KCTC14945BP, has been shown to increase immune response by enhancing phagocytosis, NK cell activity, and cytokine production. It also exhibits probiotic characteristics like antibiotic sensitivity, γ-hemolytic activity, acid resistance, and bile resistance. The strain can be used in compositions like pharmaceuticals, foods, and feeds for immune system support.

Source

Lactobacillus reuteri strain MG5462 with immune-enhancing activity that can improve immunity. The strain stimulates immune responses by activating signaling pathways like NF-κB and MAPK in macrophages, leading to increased production of immune molecules like nitric oxide, TNF-α, IL-6, iNOS, and COX-2. This makes Lactobacillus reuteri MG5462 a probiotic with potential immune-boosting benefits.

Source

Lactic acid bacterium strain Lactobacillus sakei MG-LAB279 for improving immune function, preventing viral infections, reducing stress, and suppressing inflammation. The strain enhances production of immune cytokines like IL-12p70 and IFN-λ when consumed. This promotes immune responses against viruses, activates NK cells, and reduces virus replication. It also alleviates stress and inflammation. The strain can be used in foods, beverages, and pharmaceuticals to boost immune health and viral prevention.

Source

Immunogenic probiotic compositions containing specific strains of Lactobacillus reuteri to enhance vaccine responses and stimulate the immune system. The compositions can be administered alone or in combination with vaccines to improve vaccine efficacy and duration of immunity, particularly for respiratory diseases. The Lactobacillus reuteri strains have specific sequences that when administered promote a stronger immune response when combined with vaccines. The compositions can also be used to increase antibody titers and decrease viral loads.

Source

Using live bacteria and prebiotics to increase interferon beta (IFNβ) in the gut to prevent or treat inflammatory conditions like autoimmune diseases, allergies, and viral infections. The method involves administering a live bacteria like Bifidobacterium infantis along with prebiotic oligosaccharides to stimulate endogenous IFNβ production in the gut. This elevated IFNβ level provides protective immunity against inflammatory diseases and viruses. It also reduces inflammation-associated cytokines that contribute to allergies and autoimmunity. The live bacteria and prebiotics can be delivered as a supplement or in foods to increase IFNβ in specific populations at risk for inflammatory disorders.

Source

Recombinant microbes with reduced colonization properties for use as therapeutic delivery vehicles. The microbes have reduced expression/activity of proteins involved in adhesion to host tissues. This reduces the risk of the therapeutic microbes colonizing the body after delivery and causing unintended effects. The modification involves reducing sortase, fibronectin-binding proteins, autolysins, surface-layer proteins, and other factors that promote adherence.

Source

A composition for treating and preventing viral infections like COVID-19. The composition contains extracts of a bacterial strain called Lactobacillus fermentum Qi6 grown in biofilm form. The extracts inhibit viral entry and spread by modulating the immune system and potentially binding to viral receptors. The extracts also have potential antiviral proteins.

Source

A bacterial composition that can be used as a pharmaceutical, adjuvant, or food ingredient to induce proliferation of T helper 17 (Th17) cells in the gut. The composition comprises certain species of human-derived bacteria or their culture supernatants that have been shown to strongly induce Th17 cells. These bacteria can be isolated from fecal samples and cultured. Administering the bacterial composition can promote immune function and help prevent or treat diseases that benefit from a Th17 response, such as infectious diseases.

Source

Combination therapy for respiratory infections that uses immunomodulatory agents and binding agents like antibodies. The combination involves administering an agent that can bind to the infectious pathogen, like an antibody, along with an immunomodulatory agent like a probiotic. The binding agent targets and neutralizes the pathogen, while the immunomodulatory agent enhances the immune response against it. Administering the binding agent by inhalation targets the respiratory infection.

Source

Treating dysbiosis, inflammation, infection, allergy, or immune dysfunction in the gut microbiome by using prebiotics and probiotics derived from human milk. The method involves administering a concentrated human milk permeate containing human milk oligosaccharides (HMOs) along with a probiotic strain that can consume HMOs. This promotes colonization and expansion of the probiotic strain. After initial treatment with HMOs and probiotics, synthetic HMOs are given to maintain the probiotic strain. This helps prevent dysbiosis by replenishing HMOs for the probiotics. The synthetic HMOs can be administered alone when the probiotic and HMOs are discontinued.

Source

Detecting exposure of a patient to an infectious pathogen and treating the patient via analysis and classification of the patient's microbiome. The method involves detecting exposure to a pathogen, analyzing the patient's microbiome to identify opportunistic pathogens indicating disease onset/recovery, and treating the patient with a customized therapeutic composition based on the microbiome analysis.

Source

Oral compositions containing lactoferrin, probiotic bacteria, and other ingredients for treating respiratory viral infections like COVID-19. The compositions can include lactoferrin derivatives, Lactobacillus paracasei bacteria, N-acetylcysteine, and hyaluronic acid. The lactoferrin and bacteria boost antiviral immunity and inhibit virus replication.

Source

Using Bifidobacterium animalis to treat and prevent avian influenza virus infections. The Bifidobacterium animalis probiotic enhances survival and reduces lung pathology when given orally to mice infected with H7N9 avian influenza.

Source